Theogaraj E, John C D, Christian H C, Morris J F, Smith S F, Buckingham J C
Department of Cellular and Molecular Neuroscience, Division of Neuroscience and Mental Health, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom.
Endocrinology. 2005 Nov;146(11):4804-13. doi: 10.1210/en.2005-0500. Epub 2005 Aug 11.
Stress or glucocorticoid (GC) treatment in perinatal life can induce long-term changes in the sensitivity of the hypothalamo-pituitary-adrenocortical axis to the feedback actions of GCs and, hence, in GC secretion. These changes have been ascribed largely to changes in the sensitivity of the limbic system, and possibly the hypothalamus, to GCs. Surprisingly, the possibility that early life stress/GC treatment may also exert irreversible effects at the pituitary level has scarcely been addressed. Accordingly, we have examined the effects of pre- and neonatal dexamethasone treatment on the adult male pituitary gland, focusing on the following: 1) the integrity of the acute annexin 1 (ANXA1)-dependent inhibitory actions of GCs on ACTH secretion, a process requiring ANXA1 release from folliculostellate (FS) cells; and 2) the morphology of FS cells and corticotrophs. Dexamethasone was given to pregnant (d 16-19) or lactating (d 1-7 postpartum) rats via the drinking water (1 microg/ml); controls received normal drinking water. Pituitary tissue from the offspring was examined ex vivo at d 90. Both treatment regimens reduced ANXA1 expression, as assessed by Western blotting and quantitative immunogold labeling. In particular, the amount of ANXA1 located on the outer surface of the FS cells was reduced. By contrast, IL-6 expression was increased, particularly by the prenatal treatment. Pituitary tissue from untreated control rats responded to dexamethasone with an increase in cell surface ANXA1 and a reduction in forskolin-induced ACTH release. In contrast, pituitary tissue from rats treated prenatally or neonatally with dexamethasone was unresponsive to the steroid, although, like control tissue, it responded readily to ANXA1, which readily inhibited forskolin-driven ACTH release. Prenatal dexamethasone treatment reduced the size but not the number of FS cells. It also caused a marked reduction in corticotroph number and impaired granule margination without affecting other aspects of corticotroph morphology. Similar but less marked effects on pituitary cell morphology and number were evident in tissue from neonatally treated rats. Our study shows that, when administered by a noninvasive process, perinatal GC treatment exerts profound effects on the adult pituitary gland, impairing the ANXA1-dependent GC regulation of ACTH release and altering the cell profile and morphology.
围产期的应激或糖皮质激素(GC)治疗可诱导下丘脑-垂体-肾上腺皮质轴对GC反馈作用的敏感性发生长期变化,进而影响GC的分泌。这些变化很大程度上归因于边缘系统以及可能下丘脑对GC敏感性的改变。令人惊讶的是,早期生活应激/GC治疗可能在垂体水平也产生不可逆影响这一可能性几乎未被探讨。因此,我们研究了产前和新生期地塞米松治疗对成年雄性垂体的影响,重点关注以下方面:1)GC对促肾上腺皮质激素(ACTH)分泌的急性膜联蛋白1(ANXA1)依赖性抑制作用的完整性,这一过程需要ANXA1从滤泡星状(FS)细胞释放;2)FS细胞和促肾上腺皮质激素细胞的形态。通过饮用水(1微克/毫升)给怀孕(第16 - 19天)或哺乳期(产后第1 - 7天)的大鼠给予地塞米松;对照组给予正常饮用水。在第90天对后代的垂体组织进行离体检查。通过蛋白质免疫印迹和定量免疫金标记评估,两种治疗方案均降低了ANXA1的表达。特别是,位于FS细胞外表面的ANXA1量减少。相比之下,白细胞介素-6(IL - 6)的表达增加,尤其是产前治疗组。未处理的对照大鼠的垂体组织对地塞米松的反应是细胞表面ANXA1增加,以及福斯高林诱导的ACTH释放减少。相反,产前或新生期用地塞米松治疗的大鼠的垂体组织对该类固醇无反应,尽管与对照组织一样,它对ANXA1反应迅速,而ANXA1能轻易抑制福斯高林驱动的ACTH释放。产前地塞米松治疗减少了FS细胞的大小但未减少其数量。它还导致促肾上腺皮质激素细胞数量显著减少并损害颗粒边缘化,而不影响促肾上腺皮质激素细胞形态的其他方面。在新生期治疗大鼠的组织中,对垂体细胞形态和数量也有类似但不太明显的影响。我们的研究表明,当通过非侵入性方式给药时,围产期GC治疗对成年垂体有深远影响,损害了ANXA1依赖性的GC对ACTH释放的调节,并改变了细胞分布和形态。